Sentences with phrase «diabetes and cardiovascular disease on»

Sex difference in development of diabetes and cardiovascular disease on the way from obesity and metabolic syndrome

Not exact matches

On one side of the argument we have public health associations, non-governmental organisations (NGOs) and consumer groups looking for effective solutions to address the growth of lifestyle diseases, including obesity, diabetes and cardiovascular disease.

Eating butter has no effect on raising cardiovascular disease (CVD) risk and may even have protective effects against diabetes, according to a review.

His research focuses on two major themes: (a) clinical research in cardiovascular disease and diabetes and (b) research related to food policy and the dietary determinants of ill health.

Of note, our models may underestimate the true maternal costs of suboptimal breastfeeding; we modeled the effects of lactation on only five maternal health conditions despite data linking lactation with other maternal health outcomes.46 In addition, women in our model could not develop type 2 diabetes mellitus, hypertension, or MI before age 35 years, although these conditions are becoming increasingly prevalent among young adults.47 Although some studies have found an association between lactation and rates of postmenopausal diabetes22, 23 and cardiovascular disease, 10 we conservatively limited the duration of lactation's effect on both diabetes and MI.

Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes

Former studies have already proven that smoking during pregnancy can harm the unborn child: Newborns from smoking mothers have shown low birth weights and impaired lung functions; later on in life respiratory diseases, diabetes type II, asthma or cardiovascular diseases were also more common.

Obesity puts a large burden on the health care system and increases an individual's risk for a number of diseases including diabetes, cardiovascular disease and cancer.

Higher dairy consumption has been associated with beneficial effects on cardiovascular disease - related comorbidities such as hypertension, type 2 diabetes, and insulin resistance.

Health is high on the agenda in many countries with efforts to get more people exercising in order to reduce the problems associated with obesity, such as diabetes, cardiovascular disease and cancer.

These subprojects will focus on aging - associated diseases (such as Alzheimer's disease, cardiovascular diseases, diabetes, muscle weakness) and on various forms of cancer such as neuroblastoma, colon, or breast cancer.

What the researchers found using this technique could have significant impact on both the understanding and treatment of obesity, diabetes and cardiovascular disease.

«Effectively treating obesity is crucial if we are going to be able to address the devastating impact diabetes and cardiovascular disease have on public health,» Bray said.

Raydiance's technology has attracted the attention of the U.S. Food and Drug Administration (FDA), which in July 2007 signed the company to a two - year cooperative research and development agreement that has allowed the FDA's Center for Devices and Radiological Health (CDRH) to evaluate the use, safety and effectiveness of Raydiance's USP laser system in a number of areas, including the ablation of corneal tissues in refractive surgery and corneal repair; the administration of light therapy for treating cancer, cardiovascular disease and diabetes; and the removal of plaque on teeth without damaging the enamel.

Deficiencies, excesses and imbalances in diet can produce negative impacts on health, which may lead to diseases such as cardiovascular disease, diabetes, scurvy, obesity or osteoporosis, as well as psychological and behavioral problems.

Between 1970 and 2010, female deaths in this age group from cardiovascular disease and diabetes fell on average by 66 % in 11 affluent countries: Chile, France, Germany, Greece, Japan, New Zealand, Mexico, Poland, the Russian Federation, the United Kingdom and the United States of America, the study showed.

Appel and Sacks led three earlier clinical trials that tested ways to reduce the risk of cardiovascular disease and diabetes, providing volunteers with carefully designed diets and measuring the effects on key health indicators.

The results showed that normal physical fitness, even up to 20 % below the population average, is sufficient to have a preventive effect on five of the eight risk factors affecting people with cardiovascular disease — abdominal circumference, diabetes, hypertension, obesity, and excess weight.

The data gathered for the QUALITY study (family study on the prevention of cardiovascular disease and Type 2 diabetes in kids and teens) was ideal for verifying children's dental health.

Globorisk measures cardiovascular risk in individuals aged 40 or older by factoring in the person's smoking status, blood pressure, diabetes status, and total cholesterol level, whilst adjusting for the effects of sex and age on cardiovascular disease between countries.

We are currently working on solutions that target diabetes (insulin) and cardiovascular disease (Apo AI and Apo AIMilano).

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trandiabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) tranDiabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) tranDiabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) tranDiabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Metabolic research focuses on better understanding basic biological mechanisms that regulate metabolism and how they are dysregulated in disorders such as obesity, diabetes, cardiovascular disease, and cancer.

Even small increases in activity at a population level could have far - reaching positive impacts on chronic diseases such as diabetes, cardiovascular diseases, and several cancers [1 - 4].

«Being overweight can lead to cardiovascular disease and type 2 diabetes which is also on the increase in children,» said study co-author Michelle Miller, of the University of Warwick in England.

The lean members of my family also battle these diseases, which is why I know that education on cardiovascular disease and diabetes prevention should not be limited to people in larger bodies.

A recent review published in the European Journal of Nutrition of the existing research on dairy fat came to some surprising conclusions: People who eat full - fat dairy are no more likely to develop cardiovascular disease and type 2 diabetes than people who stick to low - fat dairy.

Reportedly, it has been used in the treatment of a number of health conditions which include brittle bone, hair, teeth and nails, white spots on nails, gingivitis, tonsillitis, inflammation of the mucous membranes of the mouth, rheumatic disorders, edema, osteoarthritis, diabetes, acne, wounds, itchiness, rashes, burns, frostbite, chilblains, athlete's foot, cracked and tired feet, drawing out pus from boils and carbuncles, ulcers, fistulas, herpes simplex, dyspepsia (impaired digestion), gastrointestinal conditions, cardiovascular diseases, respiratory tract infections, bronchitis, fever, malaria, bladder problems, urinary tract infection, bed wetting in children, kidney stones (nephrolithiasis), prostate problems, hemorrhoids, muscle cramps, tumors, broken bones, fractures, sprains, nose bleed and other heavy bleeding.

However, researchers in the Department of Animal Science at Texas A&M University have published the only two research studies that actually compared the effects of ground beef from grass - fed cattle and traditional, grain - fed cattle on risk factors for cardiovascular disease (CVD) and type II diabetes in men.

Now it exists in multiple forms in most of the prepared food available to us (even the sugar - free options) and it perpetuates overall inflammation, dumps fat on our liver (non-alcoholic fatty liver disease); makes our cells resistant to the effects of insulin (insulin resistant); and then gives us metabolic syndrome, abdominal obesity, cardiovascular disease and type II diabetes.

It's also an anti-inflammatory agent that protects against cardiovascular disease, arrhythmias and sudden death after heart attack.1 And if that weren't impressive enough, berberine's up - and - coming claim to fame revolves around its truly remarkable effects on blood sugar and diabetes contrand sudden death after heart attack.1 And if that weren't impressive enough, berberine's up - and - coming claim to fame revolves around its truly remarkable effects on blood sugar and diabetes contrAnd if that weren't impressive enough, berberine's up - and - coming claim to fame revolves around its truly remarkable effects on blood sugar and diabetes contrand - coming claim to fame revolves around its truly remarkable effects on blood sugar and diabetes contrand diabetes control.

«Diet has tremendous effects on our short - and long - term health, especially when it comes to obesity, diabetes, and heart disease,» says Dariush Mozaffarian, MD, associate professor of cardiovascular medicine at Harvard Medical School.

The PCOS Awareness Symposium featured some of the world's leading experts on PCOS and covered the pathophysiology and psychology of polycystic ovary syndrome; ways to reduce risks for infertility, diabetes, cardiovascular disease, cancer, and other PCOS complications; nutrition, hair removal and medical treatment options for women and girls with PCOS.

Newer research confirms many of the old findings on these chemicals — endocrine disruption (in adults and babies), thyroid disruption, and increase risk of cardiovascular disease, diabetes and liver enzyme abnormalities.3 And recently, the Yale School of Medicine found that BPA «causes the loss of connections of brain cells,» which increases the risk for memory problems and even depressioand babies), thyroid disruption, and increase risk of cardiovascular disease, diabetes and liver enzyme abnormalities.3 And recently, the Yale School of Medicine found that BPA «causes the loss of connections of brain cells,» which increases the risk for memory problems and even depressioand increase risk of cardiovascular disease, diabetes and liver enzyme abnormalities.3 And recently, the Yale School of Medicine found that BPA «causes the loss of connections of brain cells,» which increases the risk for memory problems and even depressioand liver enzyme abnormalities.3 And recently, the Yale School of Medicine found that BPA «causes the loss of connections of brain cells,» which increases the risk for memory problems and even depressioAnd recently, the Yale School of Medicine found that BPA «causes the loss of connections of brain cells,» which increases the risk for memory problems and even depressioand even depression.4

This study, supported by The National Institutes of Health, looked at a group of 148 men and women, without cardiovascular disease or diabetes, and placed them either on a low - fat diet or low carbohydrate diet.

It increases your risk of heart disease and brings on fatal and non-fatal heart attacks, strokes and other cardiovascular events 15 years earlier than in those without diabetes, as well as significantly shortens your lifespan.

Meckling KA, O'Sullivan C, Saari D. Comparison of a low - fat diet to a low - carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free - living, overweight men and women.

1935 Effects of the high carbohydrate - low calorie diet upon carbohydrate tolerance in diabetes mellitus 1955 Low - fat diet and therapeutic doses of insulin in diabetes mellitus 1958 Effect of rice diet on diabetes mellitus associated with vascular disease 1976 Beneficial effects of a high carbohydrate, high fiber diet on hyperglycemic diabetic men 1977 Effect of carbohydrate restriction and high carbohydrates diets on men with chemical diabetes 1979 High - carbohydrate, high - fiber diets for insulin - treated men with diabetes mellitus 1981 High carbohydrate high in fibre diet in diabetes 1982 Response of non-insulin-dependent diabetic patients to an intensive program of diet and exercise 1983 Long - term use of a high - complex - carbohydrate, high - fiber, low - fat diet and exercise in the treatment of NIDDM patients 1994 Diet and exercise in the treatment of NIDDM: the need for early emphasis 1999 Toward improved management of NIDDM: A randomized, controlled, pilot intervention using a lowfat, vegetarian diet 2005 The effects of a low - fat, plant - based dietary intervention on body weight, metabolism, and insulin sensitivity 2006 A low - fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes 2006 Effect of short ‐ term Pritikin diet therapy on the metabolic syndrome 2009 A low - fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74 - wk clinical trial

The incidence of diabetes, cancer, cardiovascular disease and brain atrophy was reduced in animals on the calorie restricted diet compared with monkeys on the control diet.

This may explain why munching on nuts is correlated with a reduced risk of cardiovascular disease and type 2 diabetes.

It perpetuates overall inflammation, dumps fat on your liver (non-alcoholic fatty liver disease); makes your cells resistant to the effects of insulin (insulin resistant); and then gives you metabolic syndrome, abdominal obesity, cardiovascular disease and type II diabetes.

R.L., et al. «A brief but comprehensive lifestyle education program based on yoga reduces risk factors for cardiovascular disease and diabetes mellitus.»

His primary focus is on risk assessment, prevention, and drug - free treatment strategies for cardiovascular disease and diabetes, as well as general healthy aging.

Obesity isn't aesthetically pleasing, but it also paves the way for many physical and psychological problems including type 2 diabetes, cardiovascular disease, and nearly every other disease on the planet.

Greater consumption of fruits and vegetables (5 - 13 servings or 2 1/2 - 6 1/2 cups per day depending on calorie needs) is associated with a reduced risk of stroke and perhaps other cardiovascular diseases, with a reduced risk of cancers in certain sites (oral cavity and pharynx, larynx, lung, esophagus, stomach, and colon - rectum), and with a reduced risk of type 2 diabetes (vegetables more than fruit).

Randomized clinical trials and epidemiologic studies have shown that individuals who consume higher amounts of added sugar, especially sugar - sweetened beverages, tend to gain more weight7 and have a higher risk of obesity,2,8 - 13 type 2 diabetes mellitus,8,14 - 17 dyslipidemias, 18,19 hypertension, 20,21 and cardiovascular disease (CVD).14, 22 Most previous studies have focused on sugar - sweetened beverages but not total added sugar, and none of these studies has used nationally representative samples to examine the relationship between added sugar intake and CVD mortality.

Physical health was defined as diabetes and cardiovascular disease (coronary heart disease and stroke, CVD) based on self - reports which were validated using the study clinical examination, Hospital Episode Statistics data, and by contacting general practitioners for confirmation when no other external source existed.

On the baseline questionnaires, we requested information about age; weight and height; smoking status; physical activity; history of diabetes in first - degree relatives; use of postmenopausal hormone therapy; use of oral contraceptives; and personal history of diabetes, cardiovascular diseases, and cancers.

So back on point, it's a known fact that chronic sleep deprivation has been tied to an increased risk of type 2 diabetes, cardiovascular disease, obesity, and depression.

Immune system degeneration, neurological system disorders, cancer, arthritis, diabetes, multiple sclerosis, obesity, cardiovascular disease, kidney failure, and even reproductive system disorders, the list goes on and on.